Vistagen Therapeutics Inc (VTGN) - News Archive

: Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, continues to advance its neuroscience initiatives. With a focus on using nose-to-brain neurocircuitry, the company is developing intranasal pro...

Recent developments in the field of neuropharmacology have opened new avenues for the treatment and understanding of psychiatric disorders, particularly social anxiety disorder (SAD). This article reviews the latest ini...

Exploring New Frontiers in the Treatment of Social Anxiety Disorder: Vistagen s Focus on Intranasal Pherine Therapies In the complex and evolving landscape of mental health treatment, Social Anxiety Disorder (SAD) remai...

Vistagen Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, is actively engaged in the development of innovative therapies for psychiatric and neurological disorders. As part of its c...

In a significant advancement for mental health treatment, Vistagen Therapeutics, a neuroscience-focused biopharmaceutical company based in South San Francisco, has announced the commencement of its PALISADE-4 Phase 3 cl...

Vistagen Expands Global Intellectual Property Portfolio with New Patents for Migraine Treatment and Reports Positive Results for PH15 StudyVistagen, a clinical-stage neuroscience-focused biopharmaceutical company, has r...

SOUTH SAN FRANCISCO, Calif. - Vistagen (Nasdaq: VTGN), the neuroscience-focused biopharmaceutical company, celebrated a year of extraordinary achievements as it recently announced its fiscal year 2024 financial results...

Vistagen, a neuroscience-focused biopharmaceutical company, has recently released its financial results for the fiscal year ended March 31, 2024. The company s groundbreaking approach to developing therapies for psychia...

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueVistagen, a leading biopharmaceutical company specializing in neuroscience therapie...